Delivery Order SPE2DB22D2214-SPE2DB25FS6LU
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of XCOPRI 50 MG tablets (30-count packages) valued at $7,622.85. This firm fixed-price delivery order represents a non-competitive award and carries an ultimate completion date of August 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $3,219.60 to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count units) with an ultimate completion date of August 28, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor headquartered in Conshohocken, Pennsylvania. The contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a $2,566.61 firm fixed price delivery order to AmerisourceBergen Drug Corp for XCOPRI 150 MG tablets (30-count units) with an ultimate completion date of July 29, 2025. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The contract will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. XCOPRI (cenobamate) is...
- The Defense Logistics Agency awarded a delivery order valued at $3,536.88 to AmerisourceBergen Drug Corp for XCOPRI 200 mg tablets (30-count units) under a firm fixed price contract. The award was made on July 30, 2025, with a completion date of July 31, 2025, and performance will be executed at the vendor's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designation, reflecting the vendor's established capability to meet federal...
- AmerisourceBergen Drug Corp was awarded a delivery order on September 4, 2025, for XCOPRI 150 mg tablets (30-count) under a firm fixed-price contract valued at $3,546.33. The award was issued by the Defense Logistics Agency, a defense-focused federal procurement entity, with performance to be completed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitive, non-set-aside award and is a child contract issued under the company's...
- The Defense Department's Medical Supply Chain awarded a $1,286.70 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for XCOPRI 50-100 MG Titration Pak pharmaceutical supplies. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 29, 2025, with performance at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 5, 2025, by the Defense Logistics Agency for the supply of Xcopri 100 mg tablets (30-count package) with a ceiling value of $4,846.14. This competitively awarded, firm fixed-price delivery order is set to be completed by August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $2,830.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xcopri 200 mg tablets (30-count). The contract, which is set to complete by August 20, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xcopri 150 mg tablets (30-count units) with a ceiling value of $1,178.96. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The contract was competitively awarded without set-aside designation and is scheduled for...
- The Defense Logistics Agency awarded a $7,634.79 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count units) with an ultimate completion date of September 9, 2025. This non-set-aside contract represents a competitively awarded transaction under the company's existing indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB25FS6LUDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,178.96 to AmerisourceBergen Drug Corp for XCOPRI 25 mg tablets (30-count package). The contract, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed-price delivery order with no set-aside designation. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support mechanism for military healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency and military healthcare programs. The company's extensive portfolio of federal contracts demonstrates its capability to supply a wide range of pharmaceutical products competitively, including specialty medications, brand-name and generic drugs, and medical devices across multiple therapeutic domains. XCOPRI (cenobamate) is an antiepileptic medication, consistent with the company's role in providing neurological treatments and specialized pharmaceuticals to federal healthcare systems through the DLA's pharmaceutical distribution network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/8/25 |